Digital Healthcare Revolution: Rapid Growth of AI-Based Medical Diagnostics and Market Outlook
Editor
As of December 2025, the global digital healthcare market is experiencing unprecedented growth, driving fundamental changes in the healthcare industry. According to the latest report by McKinsey & Company, the global digital healthcare market is expected to reach $659 billion by 2025, representing an 18.6% increase from the previous year. Particularly, the AI-based medical diagnostics sector is leading the market with an annual growth rate of 24.3%. The rapid growth is attributed to a combination of increased demand for telemedicine post-COVID-19, advancements in AI technology, and governmental support for digital healthcare policies worldwide.
In Korea, the government plans to invest 2.3 trillion won over the next five years to support the development of AI-based medical diagnostic technology, as part of the ‘Digital Healthcare Innovation Strategy 2025-2030’. This demonstrates Korea’s strong commitment to securing global competitiveness in the digital healthcare sector. In fact, Korea’s digital healthcare market is projected to grow to $4.7 billion by 2025, making it the third-largest in the Asia-Pacific region after China and Japan. Notably, Korean companies like VUNO, Lunit, and JLK are achieving significant recognition in the global market in the AI diagnostic solutions sector.
In the U.S. market, Teladoc Health (TDOC), based in California, reported a revenue of $682 million in the third quarter of 2025, marking an 8.7% growth compared to the same period last year. Particularly, their AI-based chronic disease management platform, ‘Chronic Care Management’, has made a significant impact in the market by demonstrating a 23% improvement in blood sugar control among diabetes patients. Additionally, Microsoft (MSFT), headquartered in Seattle, Washington, announced that its healthcare diagnostic solution ‘Healthcare Bot’, based on the Azure AI platform, processed 12 million medical consultations in the first half of 2025 alone.
Technological Innovations and Performance Benchmarks of AI Diagnostic Technology
Currently, AI-based medical diagnostic technology is showing remarkable performance improvements, driven by advancements in deep learning and computer vision technology. In particular, in the field of medical imaging diagnostics, the accuracy of AI models has reached or even surpassed that of human specialists in certain areas. For example, VUNO’s chest X-ray AI diagnostic solution ‘VUNO Med-Chest X-ray’ recorded a sensitivity of 94.3% and a specificity of 95.7% in detecting lung nodules, outperforming the average performance of experienced radiologists, which is 92.1% sensitivity and 93.4% specificity.
From a technical perspective, current AI medical diagnostic systems are primarily built on Convolutional Neural Network (CNN) architectures. The application of state-of-the-art deep learning models such as ResNet, DenseNet, and EfficientNet to medical image analysis has significantly improved diagnostic accuracy. NVIDIA’s (NVDA) Clara platform, through GPU acceleration, has reduced the processing time per CT scan image from 15 minutes to 2 minutes, which is considered a key technology for rapid diagnosis in emergency rooms. NVIDIA’s healthcare segment revenue for the third quarter of 2025 reached $1.02 billion, a 47% increase from the same period last year.
Samsung Electronics (005930) is actively developing AI chipsets for medical use, leveraging its semiconductor technology. The ‘Exynos MedAI 2400’, released in the second half of 2025, features a Neural Processing Unit (NPU) specialized for medical image processing, enhancing AI computation performance by 3.2 times compared to conventional processors. This chipset enables real-time AI diagnostics in portable ultrasound devices and portable X-ray equipment. Samsung aims to secure a 15% market share in the global medical semiconductor market by 2026.
Global Market Competition Landscape and Company Strategy Analysis
The current global AI medical diagnostics market is witnessing intense competition between established players from the U.S. and Europe and emerging powerhouses from Asia, such as Korea and China. According to market research firm Grand View Research, as of 2025, U.S. companies like IBM Watson Health, Google Health, and Microsoft Healthcare hold approximately 45% of the global AI medical diagnostics market share, while Korean companies hold 8.2% and Chinese companies 12.4%. However, in terms of growth rate, Asian companies are outpacing their U.S. counterparts, indicating potential shifts in market dynamics.
Veracyte (VCYT), headquartered in South San Francisco, California, has established a unique position in the molecular diagnostics field. The company provides cancer diagnostic solutions through AI-based genomic analysis, recording a revenue of $78.4 million in the third quarter of 2025. Notably, their ‘Afirma GSC’ test for thyroid cancer has shown to reduce unnecessary surgeries by 74%, significantly contributing to healthcare cost savings. Veracyte’s AI algorithm achieves a 96.3% accuracy in distinguishing between benign and malignant tumors by analyzing gene expression patterns.
Meanwhile, 10x Genomics (TXG), based in Pleasanton, California, is leading innovation in the single-cell analysis technology sector. Their Chromium platform can analyze millions of cells individually at once, playing a crucial role in understanding disease mechanisms at the cellular level. As of 2025, 10x Genomics’ technology is used in over 2,800 research institutions and hospitals worldwide, particularly in cancer research for tumor microenvironment analysis. The company is projected to achieve an annual revenue of $620 million in 2025, a 14% increase from the previous year.
In Korea, VUNO (326970) is solidifying its leading position in the AI medical imaging diagnostics sector. As of 2025, VUNO’s AI solutions have been adopted by 43 major university hospitals and 127 general hospitals domestically, and are commercialized in eight countries abroad, including three products approved by the U.S. FDA. Notably, their bone age assessment AI ‘VUNO Med-BoneAge’ is used in pediatrics for diagnosing growth disorders, reducing diagnostic time by 90% compared to manual methods. VUNO has set a revenue target of 18 billion won for 2025, a 35% increase from the previous year.
As competition intensifies, companies are expanding their markets with differentiated strategies. U.S. companies primarily focus on developing universal solutions using cloud-based platforms and large datasets, while Korean companies are targeting niche markets with highly specialized solutions for specific diseases or diagnostic areas. For example, VUNO achieved a 97.8% accuracy in detecting diabetic retinopathy with its retinal disease diagnostic AI, earning high praise from ophthalmologists. This case demonstrates that in-depth technology development in specialized areas can be recognized in the market over general solutions.
From an investment perspective, global venture capital investment in the digital healthcare sector totaled $14.2 billion in the first half of 2025, with AI medical diagnostics accounting for $3.4 billion, or 24% of the total. Particularly, late-stage investments of Series B and beyond accounted for 67% of the total, indicating increased interest in companies at the commercialization stage as technology matures. In Korea, through the government-led K-Digital Healthcare Fund, 120 billion won was invested in related startups in 2025, a 78% increase from the previous year.
Positive changes are also emerging in the regulatory environment. The U.S. FDA announced the ‘AI/ML-Based Software as Medical Device (SaMD) Action Plan 2.0’ in 2025, simplifying the approval process for AI-based medical devices, reducing the approval period from an average of 18 months to 12 months. The European Union (EU) also provided clear guidelines for medical AI with the implementation of the AI Act, resolving market uncertainties. Korea’s Ministry of Food and Drug Safety is also introducing the ‘AI Medical Device Fast Track System’ from the second half of 2025, aiming to complete approvals for excellent AI medical devices within six months.
From a market outlook perspective, various research institutions consistently offer positive forecasts. According to the latest report by Frost & Sullivan, the global AI medical diagnostics market is expected to grow at an annual rate of 22.1% to reach $47.8 billion by 2030. The main drivers of this growth include increased medical demand due to aging societies, the need for AI adoption to address healthcare workforce shortages, and growing interest in preventive medicine. The Asia-Pacific region is expected to see the highest growth rate of 26.8% annually, supported by policy support and technological innovation from major countries like Korea and China.
However, there are significant challenges to address alongside market growth. The biggest issue is the privacy and security of medical data. In the first half of 2025 alone, there were 47 incidents of medical data breaches worldwide, exposing information of approximately 3.2 million patients. Consequently, governments and companies are actively investing in privacy protection technologies such as Homomorphic Encryption and Differential Privacy. Additionally, the issue of bias in AI diagnostics is emerging as a critical challenge. The relatively lower diagnostic accuracy for certain races or genders continues to be raised, emphasizing the importance of building diverse training datasets.
In conclusion, as of 2025, the AI-based digital healthcare market is deemed to have entered a full-fledged growth trajectory as technological maturity and market acceptance reach a critical point. Notably, Korean companies are gaining competitiveness in the global market, emerging as a digital healthcare hub in the Asia region. Over the next five years, this market is expected to maintain continuous high growth, forming a virtuous cycle of technological innovation, regulatory easing, and investment expansion, providing significant opportunities for related companies and investors. However, companies that actively address challenges such as data privacy, AI ethics, and collaboration with healthcare professionals are expected to ultimately lead the market.
